T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
NEW YORK, May 01, 2017 -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focusing on the development of innovative cancer therapies, today announced that the Company has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 with the U.S. Securities and Exchange Commission on April 28, 2017. The annual report can be accessed on the Company’s investor relations website at http://ir.beyondspringpharma.com.
The Company will provide a hard copy of its annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to Investor Relations, BeyondSpring Inc., 28 Liberty Street, 39th Floor, New York, NY 10005 USA.
About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as an anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
About Plinabulin
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.
Investor Relations: Garth Russell / Allison Soss KCSA Strategic Communications 212.896.1250 / 212.896.1267 [email protected] / [email protected] Media Relations: Caitlin Kasunich / Amy Singh KCSA Strategic Communications 212.896.1241 / 212.896.1207 [email protected] / [email protected]
